| Three Months Ended December 31, 2022 (2021) | Twelve Months Ended December 31, 2022 (2021) |
| Revenue was SEK 3.3 M (2.9 M) | Revenue was SEK 15.3 M (10.5 M) |
| Operating profit/loss was SEK -22.6 M (-125.7 M) Net profit/loss was SEK -40.9 M (-129.9 M) | Operating profit/loss was SEK -225.7 M (-411.6 M) Net profit/loss was SEK -245.4 M (-410.9 M) |
| Basic earnings/loss per share was SEK -0.66 (-2.08) | Basic earnings/loss per share was SEK -3.93 (-6.59) |
| Diluted earnings/loss per share were SEK -0.66 (-2.08) | Diluted earnings/loss per share were SEK -3.93 (-6.59) |
Business highlights in Q4 2022
- On November 3, Saniona announced that SAN903 is ready to start the regulatory process for entering Phase 1 clinical trials.
- On December 20, Saniona announced that SAN2219 is selected as the first preclinical development candidate from its GABA-A α2/α3 activator program.
Significant events after the reporting period
- On January 17, Saniona announced successful preclinical in vivo validation for treatment of migraine in the Cephagenix joint venture program.
Comments from the CEO
“Saniona has successfully reached all the expected milestones and important inflection points for 2022 in our pipeline programs, with the exception of Tesomet, which was put on hold in March. We continue to make strong progress with our partnering efforts and are engaging in constructive discussions on structures and financial terms with several potential partners. As a result of these concrete discussions, our current objective is to establish at least two new partnerships this year, with the aim of concluding at least one by the end of H1. I’m proud of what our team has accomplished following the restructuring in 2022 and grateful for the support of our shareholders. I look forward to keeping you updated on our exciting journey in the coming year.”